Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Management of Dyslipidemia in Patients with Atherosclerotic Disease and Liver Concerns

First-Line Additional Therapy

  • The European Society of Cardiology recommends ezetimibe (10 mg daily) as the first-line addition to rosuvastatin for patients with established atherosclerotic disease and liver concerns, providing an additional 15-20% LDL-C reduction 1, 2

Rationale for Ezetimibe Selection

  • The European Heart Journal guidelines categorize patients with established atherosclerotic disease, such as atherosclerotic aorta, as very high-risk, requiring aggressive lipid management with a target LDL-C goal of <1.4 mmol/L (55 mg/dL) and at least a 50% reduction from baseline 2

Second-Line Options if LDL-C Goals Not Achieved

  • The American College of Cardiology recommends considering bempedoic acid as the next addition if LDL-C goals are not achieved with rosuvastatin plus ezetimibe, as it reduces LDL-C by an additional 15-25% and has shown a 13% reduction in major adverse cardiovascular events in statin-intolerant patients 1, 2

Third-Line Options for Very High-Risk Patients

  • The European Heart Journal guidelines suggest adding PCSK9 inhibitors (evolocumab or alirocumab) if LDL-C remains above target despite combination therapy, as they can reduce LDL-C by an additional 60% and demonstrate significant reduction in non-fatal cardiovascular events 1, 2

Special Considerations for Liver Disease

  • Regular monitoring of liver function tests is essential when managing dyslipidemia in patients with parenchymal liver disease, according to the American Association for the Study of Liver Diseases 4

Monitoring Recommendations

  • The American Heart Association recommends monitoring liver function tests before starting therapy and periodically thereafter, particularly in patients with parenchymal liver disease, and assessing LDL-C response 4-8 weeks after initiating each new therapy 3, 4